Updates

Date: 31st July, 2026 Listing Department, National Stock Exchange of India Limited Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400051 NSE Symbol: BALAXI Subject: Business Responsibility and Sustainability Report of the Company for the FY 2025-26 Dear Sir / Madam, Pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the ‘Business Responsibility and Sustainability Report’ (“BRSR”) of Balaxi Pharmaceuticals Limited (“the Company”) for the Financial Year 2025-26, which forms part of the Annual Report of the Company for the Financial Year 2025-26. The Annual Report of the Company for the Financial Year 2025-26 containing BRSR Report for the said financial year are available on the Company’s website at: https://balaxipharma.in/assets/images/articles/Balaxi_Annual_Report_2025-26.pdf This is for your information and record. Thanking You. Yours faithfully, For Balaxi Pharmaceuticals Limited Aman Purohit (Company Secretary & Compliance Officer) ICSI Membership No.: A59345 (Encl: As above) Corporate Overview Statutory Reports Financial Statements Business Responsibility & Sustainability Report 1. L25191TG1942PLC121598 3. Year of incorporation 1942 4. Registered office address 5. Corporate address 6. E-mail secretarial@balaxi.in 7. Telephone +91 40 2355 5300 8. Website www.balaxipharma.in 9. Financial year for which reporting is being done April 2025- March 2026 11. Paid-up Capital and Fifteen Thousand Only) 12. Mr. Aman Purohit, Company Secretary and who may be contacted in case of any queries on the BRSR report Compliance Officer, Telephone: +91 40 2355 5300, Email: secretarial@balaxi.in 13. Reporting boundary - Are the disclosures under this report made The disclosure under this report has been made on a on a standalone basis (i.e. only for the entity) or on a consolidated Standalone basis. basis (i.e. for the entity and all the entities which form a part of its 15. Type of assessment or assurance obtained 16. Details of business activities (accounting for 90% of the turnover): 1 Trading International Wholesale trading/distribution 100% 17. Products/Services sold by the entity ( accounting for 90% of the entity’s turnover 1 Pharmaceutical Products 464 100.00 1* 1 2 International - - - *Manufacturing facility has been established in which operations are expected to commence in H1 of FY 2026-27. Balaxi Pharmaceuticals Limited - b. What is the contribution of exports as a percentage of the total turnover of the entity ? 100% 20. Details at the end of Financial Year 1 Permanent(D) 62 51 82.26 11 17.74 2 Other than permanent(E) - - - - - 3 Total Employees (D+E) 62 51 82.26 11 17.74 4 Permanent(F) 7 6 85.71 1 14.29 5 Other than permanent(G) - - - - - 6 Total Employees(F+G) 7 6 85.71 1 14.29 1 Permanent(D) - - - - - 2 Other than permanent(E) - - - - - 3 Total Employees(D+E) - - - - - 4 Permanent(F) - - - - - 5 Other than permanent(G) - - - - - 6 Total Employees(F+G) - - - - - 21. Participation/Inclusion/Representation of Women % ( B/A) Board of directors 6 2 33.33 Key Management Personnel 4 0 0 33.33% 44.44% 35.08% 15% 42.86% 20.45% 39% 33% 30.43% 142.86% 0 125% - - - - - - Corporate Overview Statutory Reports Financial Statements 1 Balaxi Overseas Private Limited 2 Balaxi Global FZCO, Dubai Wholly owned subsidiary 100% DMCC, Dubai) 3 Wholly owned subsidiary 100% 4 Wholly owned 100% Republic of Guatemala Step-down subsidiary 5 Wholly owned 100% Dominican Republic Step-down subsidiary 6 Wholly owned 100% Step-down subsidiary 7 Wholly owned 100% DE., El Salvador Step-down subsidiary 8 Wholly owned 100% of Angola Step-down subsidiary 9 Wholly owned 100% Step-down subsidiary Note: Balaxi Healthcare Centrafrique, SARL, Centrafrique has been struck off during the financial year 2025-26 and ceased to be a Wholly owned Step-down subsidiary with effect from 10th April, 2025. During the financial year under review, Balaxi Healthcare Nicaragua was acquired as a wholly owned subsidiary of Balaxi Global FZCO with effect from 01st April, 2025. Note: Balaxi Global FZCO, Wholly Owned Subsidiary of the Company holds 100% of shares in the step-down subsidiaries. Balaxi Overseas Private Limited is Holding Company of the listed entity and it holds 63.40% of the total equity shares of the Company. Conduct: FY 2026 FY 2025 Communities Yes https://balaxipharma. in/corporate-policies Balaxi Pharmaceuticals Limited - FY 2026 FY 2025 Investors Yes (Other than https://balaxipharma. Shareholders) in/corporate-policies Shareholders Yes https://balaxipharma. in/corporate-policies Employees & Yes https://balaxipharma. in/corporate-policies Customers Yes https://balaxipharma. in/corporate-policies Value Chain Yes Partners https://balaxipharma. in/corporate-policies Other (Please -- specify ) 26. Overview of the entity’s material responsible business conduct issues Please indicate material responsible business conduct and sustainability issues pertaining to environmental and social 1 Carbon Climate change will result Ensuring Vendors/ Footprint in in stricter environmental CDMOs are in operating costs Global Supply regulations across compliance with in meeting the Chain sectors, this will increase the applicable environmental transportation cost for the environmental standards. Company. standards. 2 Diversity and Opportunity Foster a diverse and - Positive implication: the Inclusion productivity will increase that promotes equality, non-discrimination, and environment equal opportunities for all employees. this will lead to a good talent pool for the company 3 Corporate Opportunity Ensuring a good Positive implication: Governance governance and transparent practices can transparent practices interest, a higher and improved financial performance. Corporate Overview Statutory Reports Financial Statements This section is aimed at helping businesses demonstrate the structures, policies and processes put in place towards adopting the P1 P2 P3 P4 P5 P6 P7 P8 P9 1. a. Whether your entity’s policy/policies cover each principle Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes https://balaxipharma.in/corporate-policies 2. Whether the entity has translated the policy into procedures. Yes Yes Yes Yes Yes Yes Yes Yes Yes 3. Do the enlisted policies extend to your value chain partners? Yes Yes Yes Yes Yes Yes Yes Yes Yes 1. Government of Telangana Electrical Inspectorate: labels/ standards (e.g. Forest Stewardship Council, Fairtrade, Rainforest Alliance, Trustea) standards (e.g. SA 8000, 2. Certificate of Consent for Establishment under each principle. the Orange Category from the Telangana State CFO/2025-1585. 3. Government of India Ministry of commerce and industry for Petroleum and Explosives safety organisation (PESO) PESO/FPS/2025/6801/(G154501) 5. Specific commitments, goals and targets set by the entity The Company is determined to follow the path envisioned with defined timelines, if any. Guidelines on Social, Environmental & Economic Responsibilities of Business issued by the Ministry of Corporate Affairs 6. Performance of the entity against the specific commitments, The Company shall continue to monitor its performance goals and targets along-with reasons in case the same are not met. and when the need arises 7. Statement by director responsible for the business responsibility report, highlighting ESG related challenges, targets and achievements (listed entity has flexibility regarding the placement of this disclosure) 8. Details of the highest authority responsible for implementation and oversight of the Business Responsibility Director policy (ies). Telephone:+9140 23555300 Email:secretarial@balaxi.in 9. Does the entity have a specified Committee of the Board/ Yes, the Committee consists of Managing Director as Chairman along with other functional heads. If yes, details. Balaxi Pharmaceuticals Limited - P1 P2 P3 P4 P5 P6 P7 P8 P9 P1 P2 P3 P4 P5 P6 P7 P8 P [Showing first 8,000 characters — download PDF for full document]